UK PNH diagnosis takes just 6–12 months through the Leeds National Registry — but 30% of the ~600 tracked patients carry concurrent aplastic anaemia requiring dual management.
PNH is a clonal haematopoietic stem cell disorder caused by somatic PIG-A mutation, producing GPI-anchor deficiency and complement-mediated red blood cell lysis. The Leeds National PNH Service runs the UK's single national registry: approximately 600 patients on complement inhibitor therapy, plus 100–150 additional patients with small PNH clones monitored without treatment. Annual new UK diagnoses run 50–70, with a median age at diagnosis of 38–42 years and equal gender distribution.
UK PNH survival on complement inhibitor therapy now approaches that of the general population — a landmark outcome for a historically fatal disease. Around 30% of UK PNH patients have concurrent aplastic anaemia features requiring dual management: complement inhibitor alongside immunosuppressive therapy, eltrombopag, or HSCT discussion, coordinated through the Leeds multidisciplinary service and 15 JACIE-accredited NHS BMT centres.
UK PNH treatment landscape — NHS-commissioned therapy and the pending iptacopan decision
| Drug | Class | Company | MHRA/NICE Status | Key Evidence |
|---|---|---|---|---|
| Ultomiris (ravulizumab) | Anti-C5 mAb, IV q8w | AstraZeneca | NICE TA698; NHS HSS commissioned — dominant UK standard of care; 15 designated centres | HERCULES trial; approved 2018 |
| Fabhalta (iptacopan) | Oral Factor B inhibitor | Novartis | MHRA approved 2023; NICE appraisal in progress — IFR pending decision | APPLY-PNH trial: 82% haemoglobin responder rate |
Sources: MHRA and NICE TA698 commissioning documentation; APPLY-PNH trial (Novartis); Leeds National PNH Registry annual data as reported by the Leeds National PNH Service.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Leeds National PNH Registry cohort sizing
- ravulizumab-treated population characterisation
- addressable population for oral Factor B inhibition pending NICE TA outcome
Delivers
- FLAER/CD59 flow cytometry access pathway (available without tertiary referral)
- FBC/LDH/reticulocyte triage criteria
- diagnostic delay benchmarking against international registries
Delivers
- PNH-aplasia dual-management pathway
- NHS HSCT and JACIE-accredited centre network
- BCSH guideline-driven treatment sequencing for overlap patients
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Why the PIG-A somatic mutation and GPI-anchor deficiency drive complement-mediated red blood cell lysis in roughly 600 UK patients on therapy.
- How 50 to 70 new UK diagnoses a year at a median age of 38 to 42 compare against the additional 100 to 150 patients with untreated small PNH clones.
- Why UK PNH survival on complement inhibitor therapy now approaches general-population levels, a landmark outcome for a once near-uniformly fatal disease.
- How the roughly 600-patient Leeds registry cohort splits against the 30% of patients with concurrent aplastic anaemia requiring dual management.
- Why FLAER/CD59 flow cytometry access without tertiary referral drives a UK median time-to-diagnosis of just 6 to 12 months.
- What FBC, LDH, and reticulocyte triage criteria trigger PNH testing, and how UK diagnostic delay benchmarks against international registries.
- How the 30% of UK PNH patients with aplastic anaemia features are managed through combined complement inhibitor, immunosuppressive therapy, or eltrombopag.
- Why 15 JACIE-accredited NHS BMT centres coordinate HSCT discussion and treatment sequencing under BCSH overlap guidelines.
- Why ravulizumab (Ultomiris), AstraZeneca's anti-C5 mAb dosed IV every 8 weeks, is the NICE TA698-commissioned standard of care across 15 designated centres.
- How iptacopan (Fabhalta), Novartis's oral Factor B inhibitor with an 82% haemoglobin responder rate in APPLY-PNH, sits in NICE appraisal pending an IFR decision.
- What the pending NICE appraisal of iptacopan means for the addressable population currently anchored to ravulizumab under TA698.
- How the Leeds registry's NHS-commissioned cohort sizing informs the technology appraisal evidence base for oral Factor B inhibition.
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
UK PNH disease landscape is built from the Leeds National PNH Service registry data, NICE HST evidence submissions, NHS England diagnostic pathway specifications, and British Committee for Standards in Haematology (BCSH) guidelines. UK PNH epidemiology is among the best-characterised globally because NICE's HST appraisal process requires comprehensive epidemiological data as a condition of technology appraisal.
Key sources: Leeds National PNH Service annual registry reporting; NICE HST1 and TA698 evidence submissions; NHS England diagnostic pathway specification for PNH; BCSH PNH guidelines 2020. All figures carry source citations and are triangulated across multiple primary sources.
- Leeds National PNH Registry cohort size verified against Leeds National PNH Service annual reporting and NICE HST evidence submissions.
- NHS diagnostic pathway and FLAER access verified against NICE HST1/TA698 evidence submissions and NHS England diagnostic pathway specification
- PNH-aplasia overlap rate verified against BCSH PNH guidelines 2020 and Leeds National PNH Registry thrombosis and aplasia data
- NHS HSCT centre network (JACIE-accredited) verified against NHS England BMT commissioning documentation
Frequently asked questions
Commission this assessment
AXLRx PNH Disease Landscape is built for commercial, medical affairs, and market access teams that need a rigorous, evidence-based characterisation of the UK PNH patient population and the NHS access pathway. Custom assessment in 72 hours.
Specify indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.